CeriBell’s (NASDAQ:CBLL) Quiet Period Will End on November 20th

CeriBell’s (NASDAQ:CBLL) quiet period will expire on Wednesday, November 20th. CeriBell had issued 10,606,060 shares in its IPO on October 11th. The total size of the offering was $180,303,020 based on an initial share price of $17.00. During the company’s quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on CBLL. Canaccord Genuity Group increased their target price on shares of CeriBell from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday. JPMorgan Chase & Co. began coverage on shares of CeriBell in a report on Tuesday, November 5th. They set an “overweight” rating and a $32.00 price objective for the company. Bank of America initiated coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued a “buy” rating and a $32.00 target price for the company. William Blair began coverage on CeriBell in a research report on Tuesday, November 5th. They set an “outperform” rating on the stock. Finally, TD Cowen began coverage on CeriBell in a research report on Tuesday, November 5th. They issued a “buy” rating and a $31.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $31.20.

CeriBell Stock Down 3.7 %

Shares of CBLL stock opened at $26.53 on Friday. CeriBell has a 1 year low of $23.00 and a 1 year high of $29.53.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The business had revenue of $17.20 million during the quarter, compared to analysts’ expectations of $17.06 million. As a group, equities research analysts forecast that CeriBell will post -1.55 earnings per share for the current year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.